Abstract：【Objective】To evaluate the clinical and pathological characteristics, treatment modalities, and outcome of patients with brain metastases from epithelial ovarian carcinoma (EOC) in Hunan Cancer Hospital.【Methods】The clinical and pathological characteristics, treatment modalities, and outcome of 27 patients with brain metastases from EOC were analyzed from January 2010 to December 2019. 【Results】A total of 27 patients were included in this study, with a median survival time of 15 months. Performance status (PS) score, extracranial metastasis, platinum sensitivity, initial FIGO stage, and treatment modalities were related to survival. 【Conclusion】 The prognosis of patients with brain metastases from EOC is poor. Multimodal treatments contribute to improving the prognosis of patients with brain metastases from EOC.
[1] 李佳俐,易建莉,胡彦,等.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效分析[J].医学临床研究,2013, 30(5):998-999. [2] WEBB P M, JORDAN S J. Global epidemiology of epithelial ovarian cancer[J].Nat Rev Clin Oncol,2024, 21(5):389-400. [3] 郑若梅, 曹阳, 夏良斌,等.紫杉醇联合顺铂腹腔化疗治疗晚期上皮性卵巢癌的疗效及对相关因子的影响[J].医学临床研究,2019,36(9):1860-1862. [4] KUROKI L, GUNTUPALLI S R. Treatment of epithelial ovarian cancer[J].BMJ,2020, 371:m3773. [5] PAKNESHAN S, SAFARPOUR D, TAVASSOLI F, et al. Brain metastasis from ovarian cancer:a systematic review [J].J Neurooncol,2014,119(1):1-6. [6] SEHOULI J, PIETZER K, HARTER P, et al. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer:results of a German multicenter study[J].Ann Oncol,2010,21(11):2201-2205. [7] CHIANG Y C, QIU J T,CHANG C L, et al. Brain metastasis from epithelial ovarian carcinoma:evaluation of prognosis and managements-a Taiwanese gynecologic oncology group (TGOG) study [J].Gynecol Oncol,2012,125(1):37-41. [8] 杜俊瑶,杜振广,常璐,等.上皮性卵巢癌160 例预后相关因素分析[J].中国实用妇科与产科杂志,2014, 30 (6):475-477. [9] MARCHETTI C, FERRANDINA G,CORMIO G,et al. Brain metastasis in patients with EOC:clinic-pathological and prognostic factors:a multicentric retrospective analysis from MITO grop (MITO19) [J].Gynecol Oncol,2016,143(3):532-538. [10] ANUPOL N,GHAMANDS S,ODUNSI K,et al. Evaluation of prognosis factors and treatment modalities in ovarian cancer patients with brain metastases [J].Gynecol Oncol,2002,85(3):487-492. [11] LIU B L, LIU S J,BASKYS A, et al. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer [J].BMC Cancer,2014,14:829-840. [12] RATNER E, BALA M, LOUIE-GAO M, et al. Increased risk of brain metastases in ovarian cancer patients with BRCA mutations [J].Gynecol Oncol,2019,153(3):568-573. [13] DA COSTA A A B A, DOS SANTOS E S, COTRIM D P, et al. Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis [J].BMC Cancer,2019,19(1):1194. [14] STASENKO M, CYBULSKA P, FEIT N, et al. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status [J].Gynecol Oncol,2019,154(1):144-149. [15] KWON J W, YOON J H, LIM M C, et al. Treatment results and prognostic factors of brain metastases from ovarian cancer:a single institutional experience of 56 patients[J].Int J Gynecol Cancer,2018,28(8):1631-1638.
2024, Vol. 41 
